New combo therapy targets Hard-to-Treat RAS-Mutant cancers
NCT ID NCT07397338
First seen Feb 15, 2026 · Last updated Jun 23, 2026 · Updated 18 times
Summary
This study tests whether combining experimental RAS(ON) inhibitors with ivonescimab (an immunotherapy) can shrink or control advanced solid tumors that have a RAS mutation. About 370 adults with cancers like non-small cell lung cancer or colorectal cancer will receive these drugs orally or by IV. The goal is to check safety and early signs of tumor shrinkage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Eastern Connecticut Hematology and Oncology Associates
RECRUITINGNorwich, Connecticut, 06360, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Dallas
RECRUITINGIrving, Texas, 75039, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tennessee Oncology
RECRUITINGNashville, Tennessee, 37023, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RAS(ON) inhibitors (daraxonrasib, elironrasib, zoldonrasib) plus ivonescimab, with or without chemotherapy or cetuximab
What this could lead to
If successful, this could lead to a new treatment option for people with advanced solid tumors that have a RAS mutation and have stopped responding to standard therapies.
What could go wrong
This is an early-phase trial (phase 1/2) with a small number of participants, so the combination may not prove effective or safe. Side effects from the drugs are possible and not yet fully known.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.